Theravance Biopharma
- Country
- Ownership
- -
- Employees
- 99
- Market Cap
- -
- Introduction
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Clinical Trials
54
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
- Conditions
- MSA - Multiple System AtrophySymptomatic Neurogenic Orthostatic Hypotension
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 102
- Registration Number
- NCT05696717
- Locations
- 🇺🇸
Neurostudies, Inc, Port Charlotte, Florida, United States
🇺🇸Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
🇺🇸The Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 404
- Registration Number
- NCT05165485
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site site 2, Clearwater, Florida, United States
🇺🇸Theravance Biopharma Investigational Site, Cudahy, Wisconsin, United States
🇺🇸Theravance Biopharma Investigational Site #2, Spartanburg, South Carolina, United States
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
- Conditions
- Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
- Interventions
- Drug: Nezulcitinib (TD-0903) Dose ADrug: Nezulcitinib (TD-0903) Dose B
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 14
- Registration Number
- NCT05091723
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Cypress, California, United States
Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects
- Conditions
- Symptomatic Neurogenic Orthostatic HypertensionnOH
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 72
- Registration Number
- NCT04688632
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Tempe, Arizona, United States
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 14
- Registration Number
- NCT04681079
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Kansas City, Kansas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
China Approves First Once-Daily Nebulized LAMA for COPD, Triggering $7.5M Milestone for Theravance
China's NMPA has approved YUPELRI (revefenacin) as the first once-daily nebulized long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.
Ampreloxetine Shows Promise for Neurogenic Orthostatic Hypotension in MSA Patients Without Worsening Supine Hypertension
New analyses from Theravance Biopharma's Phase 3 trials demonstrate ampreloxetine's selective mechanism of action and durable target engagement in treating neurogenic orthostatic hypotension (nOH) in multiple system atrophy patients.
JAK Inhibitor Pipeline Shows Promise for Autoimmune and Inflammatory Diseases
• The Janus Kinase (JAK) inhibitor pipeline is actively being developed by multiple companies, showing promise in treating various autoimmune and inflammatory diseases. • Key companies such as Incyte, AbbVie, and Bristol Myers Squibb are advancing JAK inhibitor therapies through clinical trials and regulatory submissions. • Emerging therapies like povorcitinib, upadacitinib, and deucravacitinib have demonstrated efficacy in treating conditions like hidradenitis suppurativa, axial spondyloarthritis, and plaque psoriasis. • The JAK inhibitor market is driven by the rising prevalence of chronic diseases and substantial investments in research and development, offering targeted treatment approaches.